|
|
Substance Name: Ritonavir [USAN:USP:INN:BAN]
RN: 155213-67-5
UNII: O3J8G9O825
InChIKey: NCDNCNXCDXHOMX-XGKFQTDJSA-N
Note
- An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.
Molecular Formula
- C37-H48-N6-O5-S2
Molecular Weight
- 720.9552
Classification Codes
- Anti-HIV Agents
- Anti-Infective Agents
- Anti-Retroviral Agents
- Antiretroviral
- Antiviral
- Antiviral (COVID-19)
- Antiviral Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Enzyme Inhibitors
- HIV Protease Inhibitors
- Metabolic Side Effects of Drugs and Substances
- Protease Inhibitor
- Protease Inhibitors
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Ritonavir
- Ritonavir [USAN:USP:INN:BAN]
MeSH Heading
- Ritonavir
Synonyms
- 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
- 5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
- A-84538
- Abbott 84538
- Abbott-84538
- ABT-538
- DRG-0244
- HSDB 7160
- Norvir
- Ritonavir
- RTV
- TMC 114r
- UNII-O3J8G9O825
Systematic Name
- 2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (5S-(5R*,8R*,10R*,11R*))-
Mixture Name
- Kaletra
Registry Numbers
CAS Registry Number
- 155213-67-5
FDA UNII
- O3J8G9O825
System Generated Number
- 0155213675
Structure Descriptors
InChI
InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1InChIKey
NCDNCNXCDXHOMX-XGKFQTDJSA-NSmiles
CC(C)Toxicity
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD | oral | > 2500mg/kg (2500mg/kg) | BEHAVIORAL: ATAXIA BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 40, Pg. 2683, 1998. |
mouse | LDLo | intravenous | 65mg/kg (65mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: TREMOR BEHAVIORAL: ATAXIA | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 40, Pg. 2683, 1998. |
rat | LD | oral | > 2500mg/kg (2500mg/kg) | BEHAVIORAL: TREMOR LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 40, Pg. 2683, 1998. |
rat | LDLo | intravenous | 35mg/kg (35mg/kg) | BEHAVIORAL: ATAXIA BEHAVIORAL: TREMOR LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 40, Pg. 2683, 1998. |